Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D2 production

Joseph H. Butterfield, Catherine R. Weiler

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background: Patients with systemic mastocytosis have increased numbers of mast cells in the bone marrow and other organs, such as the liver, spleen, gastrointestinal tract and skin. Symptoms result from the local and remote effects of mediator release from mast cells and from the local effects of increased mast cell numbers in various organs. Patients with mast cell activation experience many of the same clinical symptoms as do patients with systemic mastocytosis from chronic or spontaneous release of mast cell mediators. We report 4 patients with mast cell activation symptoms from selective release of prostaglandin (PG) D2, but not histamine, and their improvement with aspirin therapy. Methods: Bone marrow biopsy specimens obtained from 4 patients with symptoms suggestive of mastocytosis were examined by tryptase immunostaining. Baseline levels of serum tryptase and urinary 11β-PGF and N-methylhistamine were obtained. In 2 of the 4 patients, urinary 11β-PGF and N-methylhistamine samples were also measured during acute symptoms. Results: Baseline increase in urinary excretion of the PGD2 metabolite 11β-PGF was found in 2 patients. In the remaining 2 patients, baseline levels of urinary 11β-PGF2 α and N-methylhistamine were normal, but during acute symptoms, the excretion of 11β-PGF increased markedly. Treatment with aspirin resulted in normalization of 11β-PGF excretion in the 2 patients with elevated baseline levels and in prevention of symptoms in all 4 patients. Conclusions: These results suggest that mast cell activation may be manifested by a selective excessive release of PGD2. These patients respond to administration of aspirin but not to antihistamines.

Original languageEnglish (US)
Pages (from-to)338-343
Number of pages6
JournalInternational Archives of Allergy and Immunology
Volume147
Issue number4
DOIs
StatePublished - Nov 2008

Fingerprint

Prostaglandin D2
Mast Cells
Dinoprost
Systemic Mastocytosis
Aspirin
Tryptases
Bone Marrow
Mastocytosis
Histamine Antagonists
Prostaglandins F
Histamine
Gastrointestinal Tract
Spleen
Cell Count

Keywords

  • Mast cell activation
  • Mastocytosis
  • Prostaglandin D

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D2 production. / Butterfield, Joseph H.; Weiler, Catherine R.

In: International Archives of Allergy and Immunology, Vol. 147, No. 4, 11.2008, p. 338-343.

Research output: Contribution to journalArticle

@article{8eadf2571e204521a85e9fc0aea889e0,
title = "Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D2 production",
abstract = "Background: Patients with systemic mastocytosis have increased numbers of mast cells in the bone marrow and other organs, such as the liver, spleen, gastrointestinal tract and skin. Symptoms result from the local and remote effects of mediator release from mast cells and from the local effects of increased mast cell numbers in various organs. Patients with mast cell activation experience many of the same clinical symptoms as do patients with systemic mastocytosis from chronic or spontaneous release of mast cell mediators. We report 4 patients with mast cell activation symptoms from selective release of prostaglandin (PG) D2, but not histamine, and their improvement with aspirin therapy. Methods: Bone marrow biopsy specimens obtained from 4 patients with symptoms suggestive of mastocytosis were examined by tryptase immunostaining. Baseline levels of serum tryptase and urinary 11β-PGF2α and N-methylhistamine were obtained. In 2 of the 4 patients, urinary 11β-PGF2α and N-methylhistamine samples were also measured during acute symptoms. Results: Baseline increase in urinary excretion of the PGD2 metabolite 11β-PGF2α was found in 2 patients. In the remaining 2 patients, baseline levels of urinary 11β-PGF2 α and N-methylhistamine were normal, but during acute symptoms, the excretion of 11β-PGF2α increased markedly. Treatment with aspirin resulted in normalization of 11β-PGF 2α excretion in the 2 patients with elevated baseline levels and in prevention of symptoms in all 4 patients. Conclusions: These results suggest that mast cell activation may be manifested by a selective excessive release of PGD2. These patients respond to administration of aspirin but not to antihistamines.",
keywords = "Mast cell activation, Mastocytosis, Prostaglandin D",
author = "Butterfield, {Joseph H.} and Weiler, {Catherine R.}",
year = "2008",
month = "11",
doi = "10.1159/000144042",
language = "English (US)",
volume = "147",
pages = "338--343",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D2 production

AU - Butterfield, Joseph H.

AU - Weiler, Catherine R.

PY - 2008/11

Y1 - 2008/11

N2 - Background: Patients with systemic mastocytosis have increased numbers of mast cells in the bone marrow and other organs, such as the liver, spleen, gastrointestinal tract and skin. Symptoms result from the local and remote effects of mediator release from mast cells and from the local effects of increased mast cell numbers in various organs. Patients with mast cell activation experience many of the same clinical symptoms as do patients with systemic mastocytosis from chronic or spontaneous release of mast cell mediators. We report 4 patients with mast cell activation symptoms from selective release of prostaglandin (PG) D2, but not histamine, and their improvement with aspirin therapy. Methods: Bone marrow biopsy specimens obtained from 4 patients with symptoms suggestive of mastocytosis were examined by tryptase immunostaining. Baseline levels of serum tryptase and urinary 11β-PGF2α and N-methylhistamine were obtained. In 2 of the 4 patients, urinary 11β-PGF2α and N-methylhistamine samples were also measured during acute symptoms. Results: Baseline increase in urinary excretion of the PGD2 metabolite 11β-PGF2α was found in 2 patients. In the remaining 2 patients, baseline levels of urinary 11β-PGF2 α and N-methylhistamine were normal, but during acute symptoms, the excretion of 11β-PGF2α increased markedly. Treatment with aspirin resulted in normalization of 11β-PGF 2α excretion in the 2 patients with elevated baseline levels and in prevention of symptoms in all 4 patients. Conclusions: These results suggest that mast cell activation may be manifested by a selective excessive release of PGD2. These patients respond to administration of aspirin but not to antihistamines.

AB - Background: Patients with systemic mastocytosis have increased numbers of mast cells in the bone marrow and other organs, such as the liver, spleen, gastrointestinal tract and skin. Symptoms result from the local and remote effects of mediator release from mast cells and from the local effects of increased mast cell numbers in various organs. Patients with mast cell activation experience many of the same clinical symptoms as do patients with systemic mastocytosis from chronic or spontaneous release of mast cell mediators. We report 4 patients with mast cell activation symptoms from selective release of prostaglandin (PG) D2, but not histamine, and their improvement with aspirin therapy. Methods: Bone marrow biopsy specimens obtained from 4 patients with symptoms suggestive of mastocytosis were examined by tryptase immunostaining. Baseline levels of serum tryptase and urinary 11β-PGF2α and N-methylhistamine were obtained. In 2 of the 4 patients, urinary 11β-PGF2α and N-methylhistamine samples were also measured during acute symptoms. Results: Baseline increase in urinary excretion of the PGD2 metabolite 11β-PGF2α was found in 2 patients. In the remaining 2 patients, baseline levels of urinary 11β-PGF2 α and N-methylhistamine were normal, but during acute symptoms, the excretion of 11β-PGF2α increased markedly. Treatment with aspirin resulted in normalization of 11β-PGF 2α excretion in the 2 patients with elevated baseline levels and in prevention of symptoms in all 4 patients. Conclusions: These results suggest that mast cell activation may be manifested by a selective excessive release of PGD2. These patients respond to administration of aspirin but not to antihistamines.

KW - Mast cell activation

KW - Mastocytosis

KW - Prostaglandin D

UR - http://www.scopus.com/inward/record.url?scp=56549084041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56549084041&partnerID=8YFLogxK

U2 - 10.1159/000144042

DO - 10.1159/000144042

M3 - Article

VL - 147

SP - 338

EP - 343

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 4

ER -